JP2022553841A5 - - Google Patents
Info
- Publication number
- JP2022553841A5 JP2022553841A5 JP2022525957A JP2022525957A JP2022553841A5 JP 2022553841 A5 JP2022553841 A5 JP 2022553841A5 JP 2022525957 A JP2022525957 A JP 2022525957A JP 2022525957 A JP2022525957 A JP 2022525957A JP 2022553841 A5 JP2022553841 A5 JP 2022553841A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- solvate
- acceptable salt
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962933179P | 2019-11-08 | 2019-11-08 | |
| US62/933,179 | 2019-11-08 | ||
| US202063046514P | 2020-06-30 | 2020-06-30 | |
| US63/046,514 | 2020-06-30 | ||
| PCT/US2020/059210 WO2021092246A1 (en) | 2019-11-08 | 2020-11-05 | Tyk2 pseudokinase ligands |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022553841A JP2022553841A (ja) | 2022-12-26 |
| JP2022553841A5 true JP2022553841A5 (enExample) | 2023-11-13 |
| JP7635228B2 JP7635228B2 (ja) | 2025-02-25 |
Family
ID=75846491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525957A Active JP7635228B2 (ja) | 2019-11-08 | 2020-11-05 | Ｔｙｋ２偽キナーゼリガンド |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11753411B2 (enExample) |
| EP (1) | EP4054581B1 (enExample) |
| JP (1) | JP7635228B2 (enExample) |
| KR (1) | KR102938141B1 (enExample) |
| CN (1) | CN114929226B (enExample) |
| AU (1) | AU2020378345B2 (enExample) |
| BR (1) | BR112022008821A2 (enExample) |
| CA (1) | CA3160637A1 (enExample) |
| CL (1) | CL2022001178A1 (enExample) |
| CO (1) | CO2022007814A2 (enExample) |
| GE (1) | GEP20257840B (enExample) |
| IL (1) | IL292785B2 (enExample) |
| MX (1) | MX2022005563A (enExample) |
| PH (1) | PH12022551105A1 (enExample) |
| TW (1) | TWI882032B (enExample) |
| UA (1) | UA129894C2 (enExample) |
| WO (1) | WO2021092246A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS66346B1 (sr) | 2018-10-22 | 2025-01-31 | Alumis Inc | Inhibitori tyk2 i njihova upotreba |
| SG11202108619SA (en) * | 2019-02-07 | 2021-09-29 | Ventyx Biosciences Inc | Tyk2 pseudokinase ligands |
| US20220177486A1 (en) * | 2019-03-11 | 2022-06-09 | Esker Therapeutics, Inc. | Tyk2 inhibitors and uses thereof |
| SG11202110523XA (en) | 2019-03-26 | 2021-10-28 | Ventyx Biosciences Inc | Tyk2 pseudokinase ligands |
| CN114929226B (zh) | 2019-11-08 | 2024-09-27 | 温缇克斯生物科学公司 | Tyk2假激酶配体 |
| US12486274B2 (en) | 2020-01-13 | 2025-12-02 | Verge Analytics, Inc. | Substituted pyrazolo-pyrimidines and uses thereof |
| IL301385A (en) | 2020-09-16 | 2023-05-01 | Alumis Inc | TYK2 inhibitors and their use |
| KR20240111312A (ko) | 2021-10-25 | 2024-07-16 | 카이메라 쎄라퓨틱스 인코포레이티드 | Tyk2 분해제 및 이의 용도 |
| JP2025522917A (ja) * | 2022-07-06 | 2025-07-17 | ベンティックス バイオサイエンシーズ，インク． | Ｔｙｋ２阻害剤の結晶形態 |
| CN120897919A (zh) * | 2023-01-13 | 2025-11-04 | 温缇克斯生物科学公司 | Tyk2抑制剂的制备 |
| CN117247389A (zh) * | 2023-09-18 | 2023-12-19 | 南京友怡医药科技有限公司 | 一种靶向药物化合物及其制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7161003B1 (en) | 2002-09-04 | 2007-01-09 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| JP4564485B2 (ja) | 2003-02-28 | 2010-10-20 | 帝人ファーマ株式会社 | ピラゾロ［１，５−ａ］ピリミジン誘導体 |
| US7538120B2 (en) * | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| US20070082900A1 (en) * | 2005-10-06 | 2007-04-12 | Schering Corporation | Methods for inhibiting protein kinases |
| WO2010118207A1 (en) | 2009-04-09 | 2010-10-14 | Schering Corporation | Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors |
| BR122019024201B1 (pt) | 2010-05-20 | 2021-08-03 | Array Biopharma Inc | Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica |
| RS63359B1 (sr) | 2015-11-06 | 2022-07-29 | Incyte Corp | Heterociklična jedinjenja kao inhibitori pi3k-gama |
| KR102477063B1 (ko) | 2016-10-28 | 2022-12-12 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물 |
| AU2018230737B2 (en) | 2017-03-08 | 2022-09-22 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors, uses, and methods for production thereof |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| WO2018213365A1 (en) | 2017-05-15 | 2018-11-22 | Dana-Farber Cancer Institute, Inc. | Compounds for treating dengue virus infection and other viral infections |
| IL317854A (en) * | 2017-07-28 | 2025-02-01 | Takeda Pharmaceuticals Co | TYK2 inhibitors and their uses |
| EP3849981B1 (en) | 2018-09-10 | 2023-02-01 | Eli Lilly and Company | Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus |
| JP7619951B2 (ja) * | 2018-10-15 | 2025-01-22 | 武田薬品工業株式会社 | Ｔｙｋ２阻害剤およびその使用 |
| TWI800696B (zh) | 2018-12-10 | 2023-05-01 | 美商美國禮來大藥廠 | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物 |
| SG11202108619SA (en) * | 2019-02-07 | 2021-09-29 | Ventyx Biosciences Inc | Tyk2 pseudokinase ligands |
| US20220177486A1 (en) | 2019-03-11 | 2022-06-09 | Esker Therapeutics, Inc. | Tyk2 inhibitors and uses thereof |
| SG11202110523XA (en) * | 2019-03-26 | 2021-10-28 | Ventyx Biosciences Inc | Tyk2 pseudokinase ligands |
| CN114929226B (zh) | 2019-11-08 | 2024-09-27 | 温缇克斯生物科学公司 | Tyk2假激酶配体 |
-
2020
- 2020-11-05 CN CN202080092581.XA patent/CN114929226B/zh active Active
- 2020-11-05 KR KR1020227018394A patent/KR102938141B1/ko active Active
- 2020-11-05 TW TW109138709A patent/TWI882032B/zh active
- 2020-11-05 EP EP20884019.9A patent/EP4054581B1/en active Active
- 2020-11-05 MX MX2022005563A patent/MX2022005563A/es unknown
- 2020-11-05 IL IL292785A patent/IL292785B2/en unknown
- 2020-11-05 CA CA3160637A patent/CA3160637A1/en active Pending
- 2020-11-05 GE GEAP202015969A patent/GEP20257840B/en unknown
- 2020-11-05 US US17/090,805 patent/US11753411B2/en active Active
- 2020-11-05 BR BR112022008821A patent/BR112022008821A2/pt unknown
- 2020-11-05 WO PCT/US2020/059210 patent/WO2021092246A1/en not_active Ceased
- 2020-11-05 JP JP2022525957A patent/JP7635228B2/ja active Active
- 2020-11-05 PH PH1/2022/551105A patent/PH12022551105A1/en unknown
- 2020-11-05 AU AU2020378345A patent/AU2020378345B2/en active Active
- 2020-11-05 UA UAA202201178A patent/UA129894C2/uk unknown
-
2022
- 2022-05-04 CL CL2022001178A patent/CL2022001178A1/es unknown
- 2022-06-01 CO CONC2022/0007814A patent/CO2022007814A2/es unknown
-
2023
- 2023-07-06 US US18/348,296 patent/US20230348478A1/en not_active Abandoned
-
2026
- 2026-02-12 US US19/538,596 patent/US20260176281A1/en active Pending